REQUEST A DEMO
Total
USD $0.00
Search more companies

Pet Pharm Biotech Co. Ltd. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing | Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Pet Pharm Biotech Co. Ltd. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

The Company is engaged in the retail, wholesale, and manufacturing of Western medicine and Class B adult drugs. The company was established in 2011 and is headquartered in New Taipei city, Taiwan.

Headquarters
1-2F., No. 141,143, Hougang 1St Rd Xinzhuang Dist
New Taipei City; New Taipei City;

Contact Details: Purchase the Pet Pharm Biotech Co. Ltd. report to view the information.

Website: http://www.petpharmbio.com

Basic Information
Total Employees:
Purchase the Pet Pharm Biotech Co. Ltd. report to view the information.
Outstanding Shares:
Purchase the Pet Pharm Biotech Co. Ltd. report to view the information.
Financial Auditors:
Purchase the Pet Pharm Biotech Co. Ltd. report to view the information.
Incorporation Date:
January 16, 2026
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
General Manager
Company Performance
Financial values in the chart are available after Pet Pharm Biotech Co. Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
50.64%
Total operating revenue
50.64%
Operating profit (EBIT)
105.85%
EBITDA
42.12%
Net Profit (Loss) for the Period
141.01%
Total Assets
66.8%
Total Equity
83.65%
Operating Profit Margin (ROS)
0.98%
Net Profit Margin
3.6%
Return on Equity (ROE)
0.22%
Debt/Equity
-10.49%
Quick Ratio
1.71%
Cash Ratio
1.32%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?